Orchid Pharma

Orchid Pharma

712.75
-8.85
(-1.23%)
Market Cap
3,615.00 Cr
EPS
19.65
PE Ratio
42.96
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
1,997.40
52 Week Low
603.80
PB Ratio
2.89
Debt to Equity
0.25
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from3 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %

Company News

View All News
Caret
neutral
Orchid Pharma's Board of Directors approved raising funds up to Rs. 504 crores through preferential allotment or private placement of equity shares. The fundraising will be conducted in single or multiple tranches and requires member approval at a general meeting along with other statutory and regulatory approvals. The funds are specifically intended to meet minimum public shareholding requirements within the timelines stipulated under Rule 19A(5) of the Securities Contracts (Regulation) Rules, 1957.
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,593.60
#1 3,82,358.02
33.10
#1 54,729.00
9.71
#1 10,980
-19.84
39.45
6,009.00
1,59,520.07
70.63
9,712.00
18.67
2,191
26.74
43.85
1,553.40
1,25,469.33
23.63
28,409.50
7.12
5,291
9.88
57.67
3,579.10
1,21,133.01
60.27
11,539.40
6.99
1,911
19.91
51.53
1,268.10
1,05,831.96
#1 18.41
33,741.20
16.73
5,725
1.26
48.40
2,550.60
1,05,270.59
56.03
12,744.20
#1 20.90
2,007
-18.14
55.83
1,013.85
1,02,017.03
21.84
23,511.00
18.55
4,615
2.60
60.44
1,943.90
88,777.03
23.95
22,909.50
13.74
3,306
#1 51.64
50.97
31,150.00
66,191.58
47.11
6,684.70
9.64
1,414
11.55
45.41
5,333.50
63,769.99
27.89
13,458.30
3.70
2,216
21.39
57.64
Forecast
Actual
Growth Rate
Revenue Growth
24.06 %
Net Income Growth
72.28 %
Cash Flow Change
586.97 %
ROE
1.37 %
ROCE
-18.34 %
EBITDA Margin (Avg.)
10.70 %

Quarterly Financial Results

Quarterly Financials
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
141
138
137
93
120
110
105
131
95
196
164
180
134
171
169
251
185
207
228
231
252
230
226
241
184
Expenses
148
133
129
108
100
91
108
123
95
116
151
154
119
147
146
177
161
175
185
188
212
192
191
210
159
EBITDA
-7
6
7
-15
21
19
-3
8
0
79
13
26
15
24
23
74
24
32
43
42
40
38
35
32
26
Operating Profit %
-9 %
-1 %
0 %
-23 %
16 %
17 %
-5 %
-3 %
-3 %
9 %
7 %
13 %
10 %
11 %
9 %
16 %
12 %
12 %
16 %
13 %
13 %
14 %
12 %
12 %
8 %
Depreciation
31
32
32
23
30
30
29
20
20
20
20
27
22
18
8
7
8
8
9
8
8
9
9
9
9
Interest
0
0
3
1
14
13
13
12
11
10
7
5
8
9
8
8
6
4
4
4
4
3
4
4
3
Profit Before Tax
-39
-26
-28
-39
-23
-24
-45
-25
-31
49
-14
-6
-14
-3
7
59
11
20
30
30
28
26
23
19
14
Tax
0
0
0
0
0
0
0
0
0
0
0
1
1
2
-1
0
1
0
1
-3
-1
-1
2
-3
-1
Net Profit
-39
-26
-28
-39
-23
-24
-45
-25
-31
49
-14
-7
-15
-5
8
59
9
20
29
33
29
27
21
22
15
EPS in ₹
-4.32
-2.93
-3.11
-9.52
-5.55
-5.98
-10.96
-6.06
-7.57
12.10
-3.40
-1.61
-3.68
-1.32
1.86
14.49
1.85
4.30
6.18
6.81
5.79
5.37
4.10
4.40
2.94

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
4,061
3,862
3,256
3,125
3,077
1,460
1,237
1,111
1,225
1,554
1,688
Fixed Assets
1,795
1,637
1,497
1,386
1,256
858
670
584
573
620
713
Current Assets
1,278
1,251
675
679
768
569
550
398
501
791
807
Capital Work in Progress
282
280
288
272
278
26
7
10
47
31
65
Investments
0
0
1
1
1
0
15
46
44
46
326
Other Assets
1,985
1,945
1,470
1,467
1,542
576
544
472
561
857
0
Total Liabilities
4,061
3,862
3,256
3,125
3,077
1,460
1,237
1,111
1,225
1,554
1,688
Current Liabilities
1,123
1,338
1,510
2,013
2,346
175
142
241
372
260
286
Non Current Liabilities
2,609
2,475
2,212
1,905
1,436
519
442
222
165
124
135
Total Equity
329
49
-467
-792
-704
766
653
647
689
1,170
1,267
Reserve & Surplus
244
-40
-556
-881
-793
725
544
538
579
1,050
1,217
Share Capital
85
89
89
89
89
41
41
41
41
51
51

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
367
-76
-240
15
57
-2
-74
-11
18
-19
Investing Activities
1,334
-2
-176
-28
46
167
67
113
-31
-312
Operating Activities
-369
212
401
9
12
81
24
93
18
126
Financing Activities
-597
-286
-465
33
-0
-250
-165
-217
31
167

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
98.07 %
90.00 %
90.00 %
90.00 %
90.00 %
89.96 %
89.96 %
89.96 %
89.96 %
72.40 %
72.40 %
69.84 %
69.84 %
69.84 %
69.84 %
69.84 %
69.84 %
69.84 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
4.14 %
1.96 %
1.42 %
1.94 %
2.53 %
2.69 %
1.40 %
DIIs
1.00 %
3.44 %
3.35 %
3.35 %
2.97 %
2.97 %
2.98 %
3.94 %
2.62 %
13.49 %
9.88 %
14.50 %
17.73 %
18.93 %
18.29 %
18.99 %
20.10 %
19.43 %
Government
0.00 %
0.00 %
0.04 %
0.04 %
0.04 %
0.04 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.58 %
2.34 %
2.72 %
2.83 %
3.34 %
3.69 %
3.61 %
3.44 %
3.38 %
3.10 %
3.85 %
7.79 %
7.44 %
7.16 %
7.59 %
6.42 %
5.11 %
6.91 %
Others
0.35 %
4.22 %
3.89 %
3.79 %
3.65 %
3.34 %
3.44 %
2.66 %
4.03 %
11.02 %
13.87 %
3.74 %
3.03 %
2.65 %
2.35 %
2.22 %
2.27 %
2.43 %
No of Share Holders
30,343
33,379
34,798
33,535
33,698
33,679
32,717
30,894
29,523
29,039
29,197
36,931
36,720
34,695
36,363
34,158
34,303
39,827

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
20 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
20 Sept 2025 780.15 713.70
26 Oct 2015 CHANGE OF NAME Change Of Name
NA
26 Oct 2015 0.00 0.00
21 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
21 Aug 2024 1,147.85 1,398.00
11 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
11 Nov 2024 1,394.75 1,499.45
12 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Feb 2025 1,457.50 1,245.55
26 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
26 May 2025 759.20 754.40
26 Jun 2025 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
26 Jun 2025 669.00 701.95
12 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Aug 2025 800.85 780.15

Announcements

Intimation Related To The Scheme Of Amalgamation Of Dhanuka Laboratories Limited ( Amalgamating Company ) With Orchid Pharma Limited ( Amalgamated Company/Company )9 days ago
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 27, 2025
Business Responsibility and Sustainability Reporting (BRSR)Aug 27, 2025
Reg. 34 (1) Annual Report.Aug 26, 2025
Annual Report And Notice Of 32Nd Annual General Meeting Of Orchid Pharma Limited (The Company) For The F.Y. 2024-25Aug 26, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 12, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportAug 12, 2025
Intimation Of Appointment Of Auditors Of The CompanyAug 12, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 12, 2025
Outcome Of Board Meeting Inter-Alia For Consideration And Approval Of Financial Results For The Q-1 Of F.Y.2025-26 Ended On June 30 2025Aug 12, 2025
Board Meeting Outcome for Outcome Of Board MeetingAug 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2025
Announcement under Regulation 30 (LODR)-Credit RatingAug 07, 2025
Update On Purchase Of Assets Of Allecra Therapeutics SASAug 05, 2025
Board Meeting Intimation for Approval Of Unaudited Limited Reviewed Financial Results (Standalone & Consolidated) Of The Company For Quarter-1 Of F.Y.2025-26Aug 05, 2025
Purchase Of Assets Of Allecra Therapeutics Gmbh And Allecra Therapeutics SAS Related To Enmetazobactam.Jul 30, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJul 30, 2025
Intimation For Execution Of Deed Of Hypothecation In Favour Of HDFC Bank LimitedJul 17, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 14, 2025
Intimation Related To The Scheme Of Amalgamation Of Dhanuka Laboratories Limited (Amalgamating Company) With Orchid Pharma Limited (Amalgamated Company/Company) And Their Respective Shareholders And Creditors (The Scheme) Under Regulation 30 Of SEBI (LisJul 10, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJun 30, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJun 30, 2025
Closure of Trading WindowJun 26, 2025
Shareholder Meeting / Postal Ballot-Outcome of Court Convened MeetingJun 26, 2025
Intimation Of Record Date For Voting Rights Of Shareholders W.R.T. The Meeting Of Equity Shareholders Of Orchid Pharma Limited ("Company"/ "Amalgamated Company") Convened Pursuant To The Order Passed By Honble National Company Law Tribunal For ConsideringJun 09, 2025
Intimation Under Regulation 30 Of SEBI Listing Regulations- Honble National Company Law Tribunal Order To Dispose-Off Dispute On Lease Rentals With DBS Bank India Limited.Jun 06, 2025
Disclosure Of Corporate Guarantee On Behalf Of Orchid Bio-Pharma Limited (Wholly Owned Subsidiary)Jun 03, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 02, 2025
Intimation On Receipt Of EIR After The USFDA Inspection At The Plant Of The Company Situated At AlathurMay 29, 2025
Board Comments On Fine Levied By The ExchangeMay 28, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 28, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 26, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 26, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 26, 2025
Annual Audited Financial Results For The Quarter And F.Y. Ended On March 31 2025May 26, 2025
Board Meeting Outcome for Outcome Of Board Meeting For Considering And Approving Annual Audited Financial Results For The Quarter And F.Y. Ended On March 31 2025May 26, 2025
Notice Of Meeting Of Equity Shareholders And Unsecured Creditors Of Orchid Pharma Ltd Convened Pursuant To The Order Passed By Honble National Company Law TribunalMay 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2025
Board Meeting Intimation for The Board Meeting Scheduled To Be Held On May 26 2025May 20, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 15, 2025
Intimation Related To The Scheme Of Amalgamation Of Dhanuka Laboratories Limited (Amalgamating Company) With Orchid Pharma Limited (Company/ Amalgamated Company) And Their Respective Shareholders And Creditors (The Scheme) Under Regulation 30 Of SEBI (LisMay 13, 2025
Intimation Under Regulation 30 Read With Schedule III Of SEBI Listing RegulationsMay 10, 2025
Intimation On Scheme Of Amalgamation Of Dhanuka Laboratories Limited ("Amalgamating Company") With Orchid Pharma Limited ("Company"/ "Amalgamated Company") And Their Respective Shareholders And Creditors.May 03, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 11, 2025
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsApr 09, 2025
Intimation Of Letter(S)/Emails Received From Stock Exchanges As Cautionary Under SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 29, 2025
Closure of Trading WindowMar 27, 2025
Intimation Under Regulation 30- Scheme Of Amalgamation Of Dhanuka Laboratories Limited (Amalgamating Company) With Orchid Pharma Limited (Company/ Amalgamated Company) And Their Respective Shareholders And CreditorsMar 10, 2025

Technical Indicators

RSI(14)
Neutral
40.36
ATR(14)
Less Volatile
26.03
STOCH(9,6)
Oversold
11.47
STOCH RSI(14)
Oversold
6.53
MACD(12,26)
Bearish
-6.90
ADX(14)
Weak Trend
14.93
UO(9)
Bearish
37.39
ROC(12)
Downtrend And Accelerating
-6.56
WillR(14)
Oversold
-90.30

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Quant Small Cap Fund Direct Plan-Growth
0.00%
-3465947
-0.87%
-0.84%
Invesco India Contra Fund Direct-Growth
0.00%
-1044216
-0.40%
-0.44%
Kotak Multi Asset Allocation Fund Direct - Growth
0.00%
-681494
-0.62%
-0.59%
UTI Value Fund Direct-Growth
0.00%
-680645
-0.51%
-0.41%
Nippon India Pharma Fund Direct-Growth
0.00%
-492727
-0.42%
-0.41%
Invesco India Smallcap Fund Direct - Growth
0.00%
-455183
-0.44%
-0.44%
Kotak Special Opportunities Fund Direct-Growth
0.00%
-397636
-1.49%
-1.34%
UTI Small Cap Fund Direct - Growth
0.00%
-283362
-0.44%
-0.42%
Kotak Consumption Fund Direct - Growth
0.00%
-266000
-1.43%
-1.42%
Bandhan Small Cap Fund Direct-Growth
0.00%
-254952
-0.13%
-0.14%
Invesco India Multicap Fund Direct-Growth
0.00%
-205673
-0.37%
-0.44%
Kotak MNC Fund Direct-Growth
0.00%
-185228
-0.61%
-0.58%
Invesco India ELSS Tax Saver Fund Direct-Growth
0.00%
-153202
-0.40%
-0.38%
Tata India Innovation Fund Direct-Growth
0.00%
-144093
-0.61%
-0.58%
Kotak Multicap Fund Direct - Growth
0.00%
-114308
-0.04%
-0.04%
UTI Healthcare Fund Direct-Growth
0.00%
-100000
-0.65%
-0.65%
Kotak Healthcare Fund Direct - Growth
0.00%
-100000
-1.53%
-1.58%
Motilal Oswal Nifty Microcap 250 Index Fund Direct - Growth
0.00%
-51658
-0.15%
-0.14%
ITI Pharma and Healthcare Fund Direct - Growth
0.00%
-36258
-1.14%
-1.13%
Invesco India ESG Integration Strategy Fund Direct - Growth
0.00%
-34058
-0.54%
-0.50%
ITI Value Fund Direct - Growth
0.00%
-32477
-0.73%
-0.69%
UTI Conservative Hybrid Fund Direct-Growth
0.00%
-28035
-0.12%
-0.10%
PGIM India Healthcare Fund Direct-Growth
0.00%
-11805
-0.78%
-0.75%
Invesco India Equity Savings Fund Direct - Growth
0.00%
-10564
-0.18%
-0.18%
Invesco India Largecap Fund Direct-Growth
0.00%
-2369
-0.01%
-0.01%